Session Synopsis: Identifying content for genomic panels is a daunting challenge for pharma, clinicians and vendors. You want to balance the broadest selection of biomarkers that can have diagnostic impact and also inform future associations to cost/size. Dr. Weigman will highlight an approach that leverages mining millions of full text genomic articles to identify disease-gene-variant relationships within a concise platform that significantly reduces inclusion time and allows for selection of markers based on treatment, prognosis and monitoring.
Session Chair Profile
M.D., Ph.D., CSO and Co-Founder, Genomenon, Inc.
Dr. Kiel is Founder and Chief Science Officer at Genomenon where he oversees the company’s scientific direction and product development. Prior to starting Genomenon, Mark completed his residency in Clinical Pathology in 2014 at the University of Michigan. While at Michigan, he completed a fellowship in Molecular Diagnostics and devised the informatics framework for clinical next-generation sequencing in the Molecular Diagnostics Laboratory. While a post-doctoral researcher under Drs. Kojo Elenitoba-Johnson and Megan Lim, he made significant contributions to the field of Hematopathology including genomic profiling of lymphoid malignancies for which he was awarded the Benjamin Castleman Award. During his doctoral studies with Sean Morrison, he made seminal contributions to the study of hematopoietic stem cells for which he was awarded the Weintraub International Graduate Student Award and the ProQuest Distinguished Dissertation Award.
Ph.D., Director, Translational Genomics, Q2 Solutions, a Quintiles Quest Joint Venture
Dr. Victor Weigman, Ph.D. is Director, Translational Genomics at Q2 Solutions, a Quintiles Quest Joint Venture, leading the group with a goal of continued facilitation of pre-clinical drug development through biomarker identification. Ongoing research revolves around the genomic profiling of cancer using both DNA and RNA approaches including the development and deployment of robust assays that can be leveraged clinically as laboratory developed tests. Dr. Weigman brings more than 13 years of biomarker discovery research with genomics, with a majority of them dedicated to Expression Analysis (EA), a Q2 Solutions Company. He has published 14 papers on biomarker identification and assay development and has contributed to the development and launch of several genomic CLIA Assays. Dr. Weigman obtained his Ph.D. at the University of North Carolina in Biology and Bioinformatics within the Lineberger Comprehensive Cancer Center under the supervision of Charles Perou.